Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease.
Int J Geriatr Psychiatry. 1999.
PMID: 10340182
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1994 | 2 |
| 1998 | 1 |
| 1999 | 3 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 0 |
Search Results
45 results
Results by year
Citations
1
article
found by citation matching
Search results
Page 1
Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs.
J Neurosci Rural Pract. 2023 Oct-Dec;14(4):566-573. doi: 10.25259/JNRP_356_2023. Epub 2023 Oct 7.
J Neurosci Rural Pract. 2023.
PMID: 38059250
Free PMC article.
Review.
The growing prevalence of dementia makes it important for us to better understand its pathophysiology and treatment modalities, to improve the quality of life of patients and caregivers. Alzheimer's disease (AD), a neurodegenerative disease, is …
The growing prevalence of dementia makes it important for us to better understand its pathophysiology and treatment modalities, to im …
A practical algorithm for managing Alzheimer's disease: what, when, and why?
Ann Clin Transl Neurol. 2015 Mar;2(3):307-23. doi: 10.1002/acn3.166. Epub 2015 Jan 23.
Ann Clin Transl Neurol. 2015.
PMID: 25815358
Free PMC article.
Review.
Alzheimer's disease (AD) is the most common form of dementia and its prevalence is increasing. ...Pharmacologic therapy for AD should be initiated upon diagnosis. All of the currently available cholinesterase inhibitors (ChEIs; don …
Alzheimer's disease (AD) is the most common form of dementia and its prevalence is increasing. ...Pharmacologic ther …
Diagnosis, management, and treatment of Alzheimer disease: a guide for the internist.
Arch Intern Med. 1999 Apr 26;159(8):789-98. doi: 10.1001/archinte.159.8.789.
Arch Intern Med. 1999.
PMID: 10219924
Review.
Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, and laboratory studies; however, there is no definitive diagnostic test for AD. ...Other cholinesterase inhibitors are in dev …
Alzheimer disease (AD) is a diagnosis of inclusion based on patient history, physical examination, neuropsychological testing, …
Primary Palliative Care in Dementia.
Neurotherapeutics. 2022 Jan;19(1):143-151. doi: 10.1007/s13311-021-01171-x. Epub 2022 Jan 26.
Neurotherapeutics. 2022.
PMID: 35080735
Free PMC article.
Review.
Excellent primary palliative care also involves discussion of deprescribing medications of uncertain benefit such as long term use of cholinesterase inhibitors and memantine and being vigilant in the monitoring of pain with its relationship to behavioral dist …
Excellent primary palliative care also involves discussion of deprescribing medications of uncertain benefit such as long term use of cho …
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
Drugs Aging. 2023 Nov;40(11):953-964. doi: 10.1007/s40266-023-01065-x. Epub 2023 Sep 8.
Drugs Aging. 2023.
PMID: 37682445
Free PMC article.
METHODS: We sought to determine the risk of psychiatric adverse events associated with the use of AChEIs through a systematic review and meta-analysis of double-blind randomized controlled trials involving patients with Alzheimer's dementia and Parkinson's dementia. …
METHODS: We sought to determine the risk of psychiatric adverse events associated with the use of AChEIs through a systematic review and met …
Initiating and monitoring cholinesterase inhibitor treatment for Alzheimer's disease.
Int J Geriatr Psychiatry. 1999 Apr;14(4):244-8. doi: 10.1002/(sici)1099-1166(199904)14:4<244::aid-gps917>3.0.co;2-o.
Int J Geriatr Psychiatry. 1999.
PMID: 10340182
The availability of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease raises a number of clinical and ethical questions. ...Instead the primary care physician should refer potentially suitable patients for specialist asses …
The availability of acetylcholinesterase inhibitors for the treatment of Alzheimer's disease raises a num …
Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease.
J Clin Psychiatry. 1998;59 Suppl 13:23-30.
J Clin Psychiatry. 1998.
PMID: 9771827
Review.
Alzheimer's disease affects multiple domains of human brain function and has neuropsychological, neuropsychiatric, and neurologic manifestations. ...Cholinergic therapies ameliorate behavioral alteration in Alzheimer's disease, and change …
Alzheimer's disease affects multiple domains of human brain function and has neuropsychological, neuropsychiatric, and …
Effective pharmacologic management of Alzheimer's disease.
Am J Med. 2007 May;120(5):388-97. doi: 10.1016/j.amjmed.2006.08.036.
Am J Med. 2007.
PMID: 17466645
Review.
Cholinesterase inhibitor therapy with rivastigmine, donepezil, or galantamine is endorsed as standard first-line therapy in patients with mild-to-moderate Alzheimer's disease. The N-methyl-D-aspartate receptor-antagonist, memantine …
Cholinesterase inhibitor therapy with rivastigmine, donepezil, or galantamine is endorsed as standard first-line the …
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.
Drugs Aging. 2015 Jul;32(7):537-47. doi: 10.1007/s40266-015-0273-x.
Drugs Aging. 2015.
PMID: 26033268
Review.
Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase inhibitors (ChEIs) donepezil, rivastigmine, and galantamine and the N-methyl D-aspartate receptor antagonist memantine. ...While side effects are gen …
Current pharmacological therapy for Alzheimer's disease (AD) includes the cholinesterase inhibitors …
Plasma Myeloperoxidase as a Potential Biomarker of Patient Response to Anti-Dementia Treatment in Alzheimer's Disease.
J Alzheimers Dis. 2022;89(4):1483-1492. doi: 10.3233/JAD-220642.
J Alzheimers Dis. 2022.
PMID: 36057826
BACKGROUND: Myeloperoxidase (MPO), a neutrophil-derived pro-inflammatory protein, co-localizes with amyloid-beta (Abeta) plaques in Alzheimer's disease (AD). Anti-dementia treatment may facilitate efflux of Abeta and associated plaque proteins from the …
BACKGROUND: Myeloperoxidase (MPO), a neutrophil-derived pro-inflammatory protein, co-localizes with amyloid-beta (Abeta) plaques in Alzhe …
Cite